Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TK2 | O00142 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928625 | 0.78 | KCNH2 (0.44) | KCNH2KIF11HRH4MEN1OPRM1 | |
| SCHEMBL929860 | 0.78 | KIF11 (0.49) | KCNH2KIF11HRH4MEN1OPRM1 | |
| SCHEMBL930849 | 0.78 | KCNH2 (0.44) | KCNH2KIF11HRH4MEN1OPRM1 | |
| SCHEMBL12539966 | 0.75 | KIF11 (0.40) | KCNH2KIF11MEN1KMT2A | |
| SCHEMBL5477474 | 0.74 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL4050916 | 0.73 | KIF11 (0.34) | KCNH2KIF11MEN1OPRM1OPRD1 | |
| SCHEMBL4050918 | 0.73 | KIF11 (0.34) | KCNH2KIF11MEN1OPRM1OPRD1 | |
| SCHEMBL1058939 | 0.72 | KIF11 (0.38) | KCNH2KIF11HRH4MEN1OPRM1 | |
| SCHEMBL17297687 | 0.71 | KIF11 (0.61) | KIF11HRH4TK1TK2CHRM3 | |
| SCHEMBL4049049 | 0.71 | KCNH2 (0.41) | KCNH2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-1392312-A1 | TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002055083-A1 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | KCNH2 716/4885KIF11 3466/4885HRH4 135/4885 |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | KCNH2 939/4885KIF11 3322/4885HRH4 129/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | KCNH2 649/4885KIF11 3162/4885HRH4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.